A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST)

Ahrens M, Escudier B, Haanen J, Gross-Goupil M, Boleti E, Gravis G, Grimm MO, Negrier S, Bedke J, Barthelemy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Florcken A, Maroto JP, Rodriguez SC, Oosting SF, Panic A, Zschabitz S, Boegemann M, Kopecky J, Deckbar D, Hartmann A, Bergmann L (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: KARGER

City/Town: BASEL

Pages Range: 317-318

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

Authors with CRIS profile

Involved external institutions

Netherlands Cancer Institute (NKI) Netherlands (NL) Institut de Cancérologie Strasbourg (ICANS) France (FR) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE) Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg Germany (DE) Institute Paoli-Calmettes France (FR) Universitätsklinikum Tübingen Germany (DE) Institut Gustave-Roussy France (FR) University Hospital Ghent Belgium (BE) Hospital Universitario 12 de Octubre Spain (ES) University Medical Center Groningen (UMCG) / Universitair Medisch Centrum Groningen Netherlands (NL) University College London (UCL) United Kingdom (GB) Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron Spain (ES) Hospital de la Santa Creu i Sant Pau Spain (ES) Universitätsklinikum Jena Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) Centre Hospitalier Universitaire de Bordeaux / CHU Bordeaux France (FR) Universitätsklinikum Münster Germany (DE) University of Hradec Králové Czech Republic (CZ) Centre Léon-Bérard (UNICANCER) France (FR) Universitätsklinikum Essen Germany (DE) Hospital Clínic de Barcelona Spain (ES)

How to cite

APA:

Ahrens, M., Escudier, B., Haanen, J., Gross-Goupil, M., Boleti, E., Gravis, G.,... Bergmann, L. (2022). A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST). In ONCOLOGY RESEARCH AND TREATMENT (pp. 317-318). BASEL: KARGER.

MLA:

Ahrens, M., et al. "A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2022. 317-318.

BibTeX: Download